comparemela.com

Latest Breaking News On - Charles rhyee - Page 4 : comparemela.com

Veeva Systems (VEEV) Q4 2024 Earnings Call Transcript

VEEV earnings call for the period ending December 31, 2023.

Jack wallacePeter gassnerSaket kaliaBrent bowmanGunnar hansenCarolyn valenti goldman sachsKarl keirsteadGabriela borgesBrent bracelin piper sandlerSaket kalia barclaysPiper sandlerStan berenshteynAnne samuelCraig hettenbachJack wallace guggenheimPaul shawah

GoodRx (GDRX) Q4 2023 Earnings Call Transcript

GDRX earnings call for the period ending December 31, 2023.

United statesCharles rhyeeJian li evercoreStan berenshteynAllen lutzScott schoenhaus keybancMichael cherny leerinkJack wallaceJian liMichael chernyLisa gill jpmorganDaniel grosslightCraig hettenbach morgan stanleyScott schoenhausJailendra singh truistKarsten voermann

GoodRx (GDRX) Q4 2023 Earnings Call Transcript

GDRX earnings call for the period ending December 31, 2023.

United statesScott schoenhausJailendra singhDaniel grosslight citiMichael chernyStephanie davisCharles rhyeeDylan finleyJack wallaceMark mahaneyDaniel grosslightMitchell kellett guggenheimJian liScott schoenhaus keybancWhitney notaroEric sheridan goldman sachs

Evolent Health (EVH) Q4 2023 Earnings Call Transcript

EVH earnings call for the period ending December 31, 2023.

United statesAnna kruszenskiJeff garroSeth frankJessica tassanJohn johnsonWilliam blairSeth blackleyJack wallace guggenheimJenny shenRyan danielsCanaccord genuityJailendra singhKevin caliendoAndrea alfonsoDavid larsen

Evolent Health (EVH) Buy Rating Affirmed Amid Strong Q4 Results and Promising 2024 Projections

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Evolent Health (EVH – Research Report), with a price target of $63.00. Charle.

Charles rhyeeEvolent healthAnalyst charles rhyeeResearch reportTipranks premium

vimarsana © 2020. All Rights Reserved.